- Home
- KOD vs FTRE Comparison
KOD vs FTRE Comparison
Compare KOD & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOD | FTRE |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 795.5M | 864.4M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | KOD | FTRE |
|---|---|---|
| Price | $24.09 | $16.01 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 8 |
| Target Price | ★ $22.67 | $11.36 |
| AVG Volume (30 Days) | 720.6K | ★ 1.4M |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,759,900,000.00 |
| Revenue This Year | N/A | $3.17 |
| Revenue Next Year | N/A | $0.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.88 |
| 52 Week Low | $1.92 | $3.97 |
| 52 Week High | $26.21 | $20.86 |
Technical Indicators
Market Signals| Indicator | KOD | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 60.32 | 74.08 |
| Support Level | $21.24 | $15.40 |
| Resistance Level | $24.97 | $16.42 |
| Average True Range (ATR) | 1.70 | 1.03 |
| MACD | -0.16 | 0.23 |
| Stochastic Oscillator | 62.58 | 81.14 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.